Literature DB >> 8843303

Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.

R L White1, D S Burgess, M Manduru, J A Bosso.   

Abstract

An in vitro method of detecting synergy which is simple to perform, accurate, and reproducible and has the potential for clinical extrapolation is desirable. Time-kill and checkerboard methods are the most widely used techniques to assess synergy but are time-consuming and labor-intensive. The Epsilometer test (E test), a less technically demanding test, has not been well studied for synergy testing. We performed synergy testing of Escherichia coli ATCC 35218, Enterobacter cloacae ATCC 23355, Pseudomonas aeruginosa ATCC 27853, and Staphylococcus aureus ATCC 29213 with various combinations of cefepime or ceftazidime with tobramycin or ciprofloxacin using time-kill, checkerboard, and E test techniques. Time-kill testing was performed against each organism alone and in combinations at one-fourth times the MIC (1/4 x MIC) and 2 x MIC. With checkerboard tests, the same combinations were studied at concentrations ranging from 1/32 x to 4 x MIC. Standard definitions for synergy, indifference, and antagonism were utilized. E test strips were crossed at a 90 degree angle so the scales met at the MIC of each drug alone, and the fractional inhibitory concentrations index was calculated on the basis of the resultant zone on inhibition. All antimicrobial combinations demonstrated some degree of synergy against the test organisms, and antagonism was infrequent. Agreement with time-kill testing ranged from 44 to 88% and 63 to 75% by the checkerboard and E test synergy methods, respectively. Despite each of these methods utilizing different conditions and endpoints, there was frequent agreement among the methods. Further comparisons of the E test synergy technique with the checkerboard and time-kill methods are warranted.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843303      PMCID: PMC163439     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Synergism between amikacin and cefazolin against Klebsiella: in vitro studies and effect on the bactericidal activity of serum.

Authors:  J Klastersky; F Meunier-Carpentier; J M Prevost; M Staquet
Journal:  J Infect Dis       Date:  1976-09       Impact factor: 5.226

2.  Clinical significance of in vitro synergism between antibiotics in gram-negative infections.

Authors:  J Klastersky; R Cappel; D Daneau
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

3.  Comparison of techniques for measurement of in vitro antibiotic synergism.

Authors:  C W Norden; H Wentzel; E Keleti
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

4.  Antimicrobial synergism--an elusive concept.

Authors:  R C Moellering
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

5.  Penicillin and gentamicin therapy for enterococcal infections.

Authors:  A J Weinstein; R C Moellering
Journal:  JAMA       Date:  1973-02-26       Impact factor: 56.272

6.  Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail.

Authors:  W K Lau; L S Young; R E Black; D J Winston; S R Linne; R J Weinstein; W L Hewitt
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

7.  Correlations between methods for measurement of synergy.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1980-09       Impact factor: 5.226

8.  Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia.

Authors:  R J Weinstein; L S Young; W L Hewitt
Journal:  J Lab Clin Med       Date:  1975-11

9.  Antimicrobial synergism in the therapy of gram-negative rod bacteremia.

Authors:  E T Anderson; L S Young; W L Hewitt
Journal:  Chemotherapy       Date:  1978       Impact factor: 2.544

10.  Methodological variation in antibiotic synergy tests against enterococci.

Authors:  R W Ryan; I Kwasnik; R C Tilton
Journal:  J Clin Microbiol       Date:  1981-01       Impact factor: 5.948

View more
  171 in total

Review 1.  A few specialized issues that should be focused on anti-HIV drug evaluation in vitro.

Authors:  Dao-min Zhuang; Jing-yun Li
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

2.  Chitosan-EDTA new combination is a promising candidate for treatment of bacterial and fungal infections.

Authors:  Amany A El-Sharif; Mohamed H M Hussain
Journal:  Curr Microbiol       Date:  2010-10-21       Impact factor: 2.188

3.  In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods.

Authors:  Thean Yen Tan; Tze Peng Lim; Winnie Hui Ling Lee; Suranthran Sasikala; Li Yang Hsu; Andrea Lay-Hoon Kwa
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

4.  Ultrashort peptide bioconjugates are exclusively antifungal agents and synergize with cyclodextrin and amphotericin B.

Authors:  Christopher J Arnusch; Hannah Ulm; Michaele Josten; Yana Shadkchan; Nir Osherov; Hans-Georg Sahl; Yechiel Shai
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

5.  Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis.

Authors:  Gani Orhan; Aysen Bayram; Yasemin Zer; Iclal Balci
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

6.  Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.

Authors:  Patrick Schwarz; Guilhem Janbon; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

7.  Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.

Authors:  Samira Dahesh; Brian Wong; Victor Nizet; George Sakoulas; Truc T Tran; Samuel L Aitken
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

8.  In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

9.  Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods.

Authors:  Nuri Kiraz; Ilknur Dag; Mustafa Yamac; Abdurrahman Kiremitci; Nilgun Kasifoglu; Yurdanur Akgun
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

10.  In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae.

Authors:  Lindley A Barbee; Olusegun O Soge; King K Holmes; Matthew R Golden
Journal:  J Antimicrob Chemother       Date:  2014-01-26       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.